Literature DB >> 18710554

Neurocysticercosis as a first presentation of tonic-clonic seizures: a case report.

Matthew J Booker1, Catherine Snelson, Louise Dodd.   

Abstract

We report the case of a 28 year-old immigrant Asian man from the Punjab region with a first presentation of seizures. This patient had no significant past medical history, but suffered several headaches in the preceding week and was pyrexial on presentation. A CT scan of his head showed a single area of subcortical low attenuation initially suggesting ischaemia. A lumbar puncture and CSF examination was unremarkable. Further investigation revealed discrete calcified gluteal lesions on pelvic X-ray, and serum immunology positive for cysticercosis. The diagnosis of neurocysticercosis was made, and the patient improved on dexamethasone and a short course of vermicide, to be discharged a week later. With increasing global migration, the prevalence of neurological parasitic infections seen in the UK is likely to rise. This case highlights the importance of careful interpretation of non-specific head CTs in the context of first presentation of seizures in a susceptible population.

Entities:  

Year:  2008        PMID: 18710554      PMCID: PMC2531088          DOI: 10.1186/1757-1626-1-104

Source DB:  PubMed          Journal:  Cases J        ISSN: 1757-1626


  4 in total

Review 1.  Neurocysticercosis: an update.

Authors:  Arturo Carpio
Journal:  Lancet Infect Dis       Date:  2002-12       Impact factor: 25.071

Review 2.  Neurocysticercosis and epilepsy in developing countries.

Authors:  D K Pal; A Carpio; J W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

Review 3.  Diagnostic criteria for neurocysticercosis: some modifications are needed for Indian patients.

Authors:  Ravindra Kumar Garg
Journal:  Neurol India       Date:  2004-06       Impact factor: 2.117

Review 4.  Cysticercosis: an emerging parasitic disease.

Authors:  Robert Kraft
Journal:  Am Fam Physician       Date:  2007-07-01       Impact factor: 3.292

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.